Study shows APOE4 disrupts bone quality in females, offering a potential early signal of neurodegenerative risk.
Alzheimer’s disease has long been framed as a disorder of the brain; yet, as the field edges toward a more systemic understanding of aging, that neat boundary is beginning to blur. New research from the Buck Institute for Research on Aging suggests that one of the condition’s most significant genetic risk factors, APOE4, may exert measurable effects far beyond neural tissue – quietly compromising bone quality in ways that evade standard clinical detection [1].
The study, published in Advanced Science, reports that female mice carrying the APOE4 variant exhibit significant deficits in bone strength despite appearing structurally normal on imaging. The mechanism, the researchers argue, lies not in bone density but in the disruption of osteocytes – long-lived cells embedded within bone that are responsible for maintaining its microarchitecture. It is a finding that begins to bridge two conditions often observed together in the clinic: osteoporosis and Alzheimer’s disease.
Longevity.Technology: There is something neatly subversive about this finding; a gene we have spent decades interrogating in the brain appears to be doing some of its most consequential early work elsewhere entirely – in the skeleton, no less. The notion that Alzheimer’s risk might first announce its presence via our bones, long before it declares itself in cognition, feels rather like a challenge to the way we compartmentalize disease; after all, osteocytes – long-lived, networked and now implicated in neurodegenerative pathways – are beginning to look suspiciously like the bone’s own neurons. More provocative still is the reminder that this biology unfolds on the basis of sex; the female-specific vulnerability observed here is not a side note but the signal, reinforcing a broader and often uncomfortable truth in longevity science – that one-size-fits-all models of aging are not merely incomplete, they are misleading. Clinically, the implications are equally unsettling: if bone quality can deteriorate invisibly, evading standard imaging while quietly tracking Alzheimer’s risk, then our current diagnostic frameworks may be calibrated to detect damage only once it is well underway – too little, too late. What emerges is a reframing of both osteoporosis and neurodegeneration – not as isolated endpoints, but as parallel expressions of a shared, systemic decline. And perhaps, if we are willing to look earlier and think more integratively, as an opportunity to intervene before either has the chance to fully take hold.
A hidden deterioration in bone quality
The distinction between bone density and bone quality is central here. While clinical practice largely relies on bone mineral density scans, these measurements can miss more subtle, material-level changes that influence fracture risk. In this study, cortical bone structure appeared unchanged; yet mechanical testing revealed that bones from female APOE4 mice were markedly more fragile, with reduced stiffness and a diminished capacity to absorb stress before breaking [1].
“What makes this finding so striking is that bone quality is being compromised at a molecular level that a standard bone scan simply will not catch,” said Professor Birgit Schilling. “APOE4 is quietly disrupting the very cells responsible for keeping bone strong, and it is doing this specifically in females, which mirrors what we see with Alzheimer’s disease risk.”
The authors describe this as a failure of perilacunar/canalicular remodeling – a process by which osteocytes maintain the microscopic network that confers resilience to bone [1]. When this system falters, the material properties of bone degrade, even if its overall structure remains intact.
Osteocytes take centre stage
The study’s deeper contribution lies in its identification of osteocytes as active participants in age-related disease. Proteomic analysis revealed that bone tissue is unexpectedly rich in proteins typically associated with neurodegeneration, including apolipoprotein E itself and amyloid precursor protein [1].
“The team discovered that bone, and particularly osteocytes, the long-lived cells embedded within it, is unusually rich in proteins associated with neurological disease, including apolipoprotein E [APOE] and amyloid precursor protein,” says Buck research scientist Charles Schurman, PhD.
Strikingly, the molecular disruption linked to APOE4 was more pronounced in bone than in the hippocampus at this stage of life, a period when cognitive symptoms remain relatively mild. As the authors note, “the scale of molecular and functional deterioration in APOE4 female bone far exceeds that observed in the brain at the same time [1].”
Sex-specific biology in focus
The fact that these changes are almost exclusively found in females isn’t just a random detail; it’s a central piece of the puzzle. We’ve known for a long time that both osteoporosis and Alzheimer’s hit women much harder than men, and this research finally provides a biological “why” for the clinical link we’ve been seeing between the two conditions for years.
One of the most telling findings from Schurman’s team was that APOE levels in the bone cells of older female mice were nearly twice those found in younger mice or even their male counterparts. This wasn’t just a broad change, either – the researchers saw a ripple effect across the entire female bone transcriptome, with shifts in hormone and metabolic pathways that look remarkably similar to the patterns we see in neurodegenerative decline [1].
Professor Lisa Ellerby, PhD, who is also a senior author of the paper, situates the findings within a broader shift in perspective: “These results suggest that osteocytes could serve as early biological sentinels for age-related cognitive decline in women carrying APOE4.” The implication is not merely diagnostic but conceptual – that the earliest signals of neurodegenerative risk may arise in peripheral tissues.
Rethinking diagnosis and intervention
Clinically, the work raises difficult questions. Nearly half of fragility fractures in older women occur in individuals without clinically defined osteoporosis, a discrepancy that has long puzzled clinicians. The current findings offer one possible explanation: bone quality, not just quantity, is being compromised.
This has implications for both screening and intervention. If osteocyte dysfunction precedes overt structural decline, then earlier detection may require new biomarkers – molecular, cellular or functional – that capture these changes before they become visible on imaging. It also opens the possibility that therapies targeting bone remodeling pathways could have wider effects on systemic aging processes.
A wider lens on aging
Perhaps the most interesting thread running through the study is its insistence on interconnectedness. The authors note that bone and brain share not only risk factors but also cellular features; osteocytes, like neurons, are long-lived, highly networked and vulnerable to metabolic stress. The pathways affected by APOE4 – mitochondrial function, immune signaling, lipid metabolism – are familiar to anyone studying aging more broadly.
“We think that targeting osteocyte function may open a new front in preserving bone quality in this population,” said Ellerby. It is a modest statement, but one that hints at a larger shift – from treating diseases in isolation to understanding how they co-evolve across tissues.
Where the signals begin
If the skeleton is indeed an early site of pathology, then the timeline of Alzheimer’s disease may need to be reconsidered. Not later, but earlier. Not confined, but distributed. And not inevitable, perhaps, if the signals can be read – and acted upon – in time.
Photographs courtesy of The Buck Institute for Research on Aging
[1] https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202523511
